Mirova Invests $903,000 in Bristol Myers Squibb Company $BMY

Key Points

• Mirova has made a new investment in Bristol Myers Squibb, acquiring 14,805 shares valued at approximately $903,000 during the first quarter of the year.
• The biopharmaceutical company reported a strong earnings per share of $1.46 for its last quarter, surpassing analyst expectations by $0.39, along with a revenue of $12.27 billion.
• Bristol Myers Squibb announced a quarterly dividend of $0.62, equating to an annual yield of 5.2%, with a current dividend payout ratio of 100%.

Mirova purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 14,805 shares of the biopharmaceutical company's stock, valued at approximately $903,000.

A number of other hedge funds have also recently made changes to their positions in BMY. Pinney & Scofield Inc. purchased a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $25,000. Park Square Financial Group LLC purchased a new position in shares of Bristol Myers Squibb during the fourth quarter worth approximately $26,000. Global Wealth Strategies & Associates raised its stake in shares of Bristol Myers Squibb by 137.5% during the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 275 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Bristol Myers Squibb in the first quarter valued at approximately $31,000. Finally, Accent Capital Management LLC purchased a new position in Bristol Myers Squibb in the 1st quarter valued at approximately $33,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on BMY shares. Daiwa America lowered Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Wall Street Zen cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. Citigroup cut their target price on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research note on Friday, August 1st. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 target price on the stock. in a research note on Tuesday, August 5th. Finally, Morgan Stanley restated a "hold" rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $56.38.

Bristol Myers Squibb Stock Performance

BMY traded up $0.09 during trading on Friday, reaching $46.97. 3,990,182 shares of the company were exchanged, compared to its average volume of 13,124,009. The stock has a market cap of $95.59 billion, a P/E ratio of 18.95, a PEG ratio of 2.44 and a beta of 0.36. The firm has a 50 day moving average of $47.04 and a 200 day moving average of $50.84. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 52 week low of $42.96 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.39. The firm had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm's revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were paid a dividend of $0.62 per share. The ex-dividend date of this dividend was Thursday, July 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.3%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 100.00%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.